Detail akcie MABION online

Business Summary: Mabion SA is a Poland-based company engaged in the research and development of biotechnological and biopharmaceutical medicinal products. Mabion SA was founded by four pharmaceutical companies, including Celon Pharma Ltd, Polfarmex Co, Genexo Ltd and IBSS Biomed Co, as well as two companies focused on research and development in biotechnology field, including BioCentrum Ltd and Biotech Consulting Ltd. The Company specializes in the humanized monoclonal antibodies (mAbs) technology, a new generation of biotechnological drugs. It focuses on oncology drugs used to treat blood cancer, lymphomas and leukemias, rheumatoid arthrisis, as well as breast cancer. It operates its own Research and Development Center in the Special Economical Zone in Lodz, Poland.
Financial Summary: BRIEF: For the three months ended 31 March 2024, Mabion SA revenues decreased 14% to PLN34M. Net income increased 7% to PLN17.5M. Revenues reflect Sale of Products decrease of 16% to PLN32.2M, Leasing decrease of 23% to PLN893K. Net Income benefited from Foreign Exchange Gain increase from PLN0K to PLN5.2M (income), R& D Expenses decrease of 77% to PLN490K (expense), Foreign Exchange Loss decrease from PLN1.6M (expense) to PLN0K.